EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Hemoperfusion with the HA330/HA380 Cartridge in Intensive Care Settings: A State-Of-The-Art Review

Yupei Li, Mei Han, Mei Yang, Baihai Su

Blood Purification · 2024

DOI: 10.1159/000542469 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Blood Purification, 2024. Verfasst von Yupei Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu, China, sculyp@163.com. Hauptthemen laut MEDLINE: Hemoperfusion, Critical Care. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 62 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Hemoperfusion with the HA330/HA380 cartridge has markedly evolved during the past decade and has thus been widely used in intensive care settings to treat critical or hyperinflammatory illnesses. Numerous clinical studies have demonstrated that HA330/HA380 hemoperfusion might mitigate systemic inflammatory response syndrome and organ dysfunction in ICU patients by removing inflammatory mediators and metabolic toxins from the blood. However, there is currently lacking a systematic evaluation on the safety and efficacy of HA330/HA380 hemoperfusion in intensive care settings. Summary: We searched the PubMed database, Chinese Clinical Trial Registry, and ClinicalTrials.gov for articles published from inception to June 20, 2024 (updated on September 10, 2024) to perform a state-of-the-art review of HA330/HA380 hemoperfusion in daily critical care practice. We discuss the basic technique characteristics and ex vivo investigations of the HA330/HA380 cartridge and summarize the latest clinical evidence regarding the use of HA330/HA380 hemoperfusion for the treatment of sepsis, severe COVID-19, cardiac surgery, acute pancreatitis, liver failure, and blunt trauma. Ex vivo studies suggest that the HA330/HA380 cartridge demonstrates satisfactory biocompatibility and substantial adsorption capacity for inflammatory cytokines, such as interleukin-6, interleukin-10, and tumor necrosis factor-α. Small-scale clinical studies indicate that HA330/HA380 hemoperfusion may help reduce plasma levels of inflammatory mediators, alleviate organ dysfunction, and improve survival in some critically ill patients with sepsis, severe COVID-19, acute pancreatitis, and blunt trauma. Key Messages: (i) The HA330/HA380 cartridge contains abundant, coated, biocompatible sorbent beads made of styrene-divinylbenzene copolymers. (ii) HA330/HA380 hemoperfusion, with or without combined continuous renal replacement therapy, is a promising treatment option for some critically ill patients by removing proinflammatory mediators and alleviating organ dysfunction. (iii) The HA330/HA380 cartridge may adversely adsorb antibiotics, and appropriate antibiotic dosing adjustment and plasma drug level monitoring is recommended. (iv) There are currently numerous ongoing clinical trials evaluating the safety and efficacy of HA330/HA380 hemoperfusion in critically ill patients who develop sepsis or undergo cardiopulmonary bypass, which will certainly sharpen our future practice of HA330/HA380 hemoperfusion in ICU.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemoperfusionCritical CareHumansMultiple Organ FailureSystemic Inflammatory Response SyndromeIntensive Care UnitsCritical IllnessCOVID-19

Stichwörter der Autor:innen

COVID-19HA330HA380HemoperfusionInflammationMortalitySepsis

Autor:innen und Institutionen

  • Department of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu, China, sculyp@163.com.
  • Department of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu, China.
  • Department of Nephrology, The First People's Hospital of Shuangliu District, Chengdu, China.
  • Med+ Biomaterial Institute of West China Hospital/West China School of Medicine, Sichuan University, Chengdu, China.
  • Med-X Center for Materials, Sichuan University, Chengdu, China.

Zitieren

APA

Li, Y., Han, M., Yang, M., & Su, B. (2024). Hemoperfusion with the HA330/HA380 Cartridge in Intensive Care Settings: A State-Of-The-Art Review. Blood Purification. https://doi.org/10.1159/000542469

Vancouver

Li Y, Han M, Yang M, Su B. Hemoperfusion with the HA330/HA380 Cartridge in Intensive Care Settings: A State-Of-The-Art Review. Blood Purification. 2024. doi:10.1159/000542469

BibTeX
@article{Li2024,
  author = {Li, Yupei and Han, Mei and Yang, Mei and Su, Baihai},
  title = {Hemoperfusion with the HA330/HA380 Cartridge in Intensive Care Settings: A State-Of-The-Art Review},
  journal = {Blood Purification},
  year = {2024},
  doi = {10.1159/000542469}
}
Kostenlos starten →